View of OUTCOME OF BEVACIZUMAB PLUS XELOX AS FIRST-LINE CHEMOTHERAPY FOR OVER 60 YEARS OLD PATIENTS WITH METASTATIC COLORECTAL CANCER

Return to Article Details OUTCOME OF BEVACIZUMAB PLUS XELOX AS FIRST-LINE CHEMOTHERAPY FOR OVER 60 YEARS OLD PATIENTS WITH METASTATIC COLORECTAL CANCER Download Download PDF